Lung Cancer News

Opioids are a potent pharmacologic option for managing recurrent pain experienced by cancer survivors.

Lorlatinib appeared superior to crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer, according to an interim analysis of the randomized phase 3 CROWN study presented at ESMO Virtual Congress 2020.

Amivantamab and lazertinib can be combined safely at their monotherapy doses for patients with advanced EGFR-mutated non-small cell lung cancer, according to results of the phase 1 CHRYSALIS study presented at ESMO Virtual Congress 2020.

Sotorasib demonstrated encouraging anticancer activity among patients with heavily pretreated advanced non-small cell lung cancer who harbor KRAS G12C mutations, according to phase 1 study results presented at ESMO Virtual Congress 2020.

Cemiplimab-rwlc monotherapy extended OS compared with first-line platinum doublet chemotherapy for certain patients with advanced non-small cell lung cancer, according to study findings presented at ESMO Virtual Congress 2020.

Radiotherapy after complete resection and neoadjuvant chemotherapy failed to significantly improve 3-year DFS among certain patients with non-small cell lung cancer, according to study results presented during ESMO Virtual Congress 2020.

Adjuvant osimertinib induced clinically meaningful reductions in central nervous system disease recurrence and death among patients with EGFR-mutated non-small cell lung cancer, according to data presented at the ESMO Virtual Congress 2020.

The FDA cleared an investigational new drug application for ATA2271, a chimeric antigen receptor T-cell therapy for the treatment of advanced mesothelioma, according to the agent’s manufacturer.

The FDA granted accelerated approval to pralsetinib for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer.

The FDA granted orphan drug designation to KN046 for the treatment of patients with thymic epithelial tumors, according to a manufacturer-issued press release.